What is the Voluntary Improvement Program?
Faster results. Higher quality. FDA-supported.
Stand out from the competition with The Case for Quality Collaborative Community Voluntary Improvement Program (VIP)—an industry-leading initiative developed by the U.S. Food & Drug Administration (FDA), CDRH, MDIC, ISACA, and leaders in the medical device community. VIP is designed to empower medical device manufacturers, drive measurable improvements, and revolutionize performance. By focusing on proactive quality enhancement, VIP helps organizations elevate product quality, improve patient outcomes, and streamline regulatory processes.
The FDA Guidance “Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program” details how the program rewards device makers’ commitment to continuous improvement by lessening regulatory burdens. More than just compliance, VIP provides a clear, structured path to operational excellence and long-term success in an increasingly competitive landscape.

REDUCTION IN COMPLAINTS
- 95%
ADDED TO ANNUAL SALES
- $15 MILLION
NCR AND CAPA REPORTS FASTER BY
- 87%
INCREASE IN DAILY PRODUCTION OF
- 65%
DECREASE IN STAFF TURNOVER
- 70%
VIP Benefits
Get involved with the Voluntary Improvement Program
- Content
- Part of lifecycle for medical devices distributed in the US (Class I, II, III)
- This can be any facility which “designs, manufactures, fabricates, assembles, or processes a finished device.”
- Can include, but is not limited to, “those who perform the functions of contract sterilization, installation, relabeling, remanufacturing, repacking, or specification development, and initial distributors of foreign entities performing these functions.”
- Companies should have all of the following:
- Prior compliance history or compliance profile (i.e. US FDA inspection or MDSAP audit)
- Site registration with US FDA
- Device listing with US FDA
- Facilities must not be under Official Action Indicated (OAI) status or subject to a judicial action. Voluntary Action Indicated (VAI) is acceptable.
- Companies with OAI can become eligible when they have provided the FDA with confirmation that appropriate corrective action has been implemented, and those actions have been verified by the FDA during a follow up inspection.
- Companies may want to seek additional eligibility information if they are a new manufacturer, start-up company, without a compliance profile, or not marketing products in the U.S.
For further guidance view the FDA guidance document “Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program.”
- Content
An experienced appraisal team will evaluate your organization’s capabilities through conversations with individual contributors, systems demonstrations, site tours, etc. This evidence is then evaluated against a proven set of best practices, the CMMI model, and the results allow the organization to easily identify areas of strength and opportunities for improvement. You’ll be empowered to prioritize opportunities that align with your business objectives, while quarterly check points provide progress tracking and guidance on improvement projects.
Crunch the Numbers for Your VIP Participation

